AU2016291701B2 - Multivalent and multispecific DR5-binding fusion proteins - Google Patents

Multivalent and multispecific DR5-binding fusion proteins Download PDF

Info

Publication number
AU2016291701B2
AU2016291701B2 AU2016291701A AU2016291701A AU2016291701B2 AU 2016291701 B2 AU2016291701 B2 AU 2016291701B2 AU 2016291701 A AU2016291701 A AU 2016291701A AU 2016291701 A AU2016291701 A AU 2016291701A AU 2016291701 B2 AU2016291701 B2 AU 2016291701B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
cancer
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016291701A
Other languages
English (en)
Other versions
AU2016291701A1 (en
Inventor
Quinn Deveraux
Brendan P. Eckelman
Abrahim HUSSAIN
Kyle S. JONES
Amir S. RAZAI
John C. Timmer
Katelyn M. WILLIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibrx Biosciences Inc
Original Assignee
Inhibrx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Biosciences Inc filed Critical Inhibrx Biosciences Inc
Publication of AU2016291701A1 publication Critical patent/AU2016291701A1/en
Assigned to Inhibrx, Inc. reassignment Inhibrx, Inc. Alteration of Name(s) of Applicant(s) under S113 Assignors: INHIBRX LP
Application granted granted Critical
Publication of AU2016291701B2 publication Critical patent/AU2016291701B2/en
Priority to AU2022291498A priority Critical patent/AU2022291498A1/en
Assigned to INHIBRX BIOSCIENCES, INC. reassignment INHIBRX BIOSCIENCES, INC. Request for Assignment Assignors: Inhibrx, Inc.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016291701A 2015-07-16 2016-07-18 Multivalent and multispecific DR5-binding fusion proteins Active AU2016291701B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022291498A AU2022291498A1 (en) 2015-07-16 2022-12-21 Multivalent and multispecific DR5-binding fusion proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
US62/193,309 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022291498A Division AU2022291498A1 (en) 2015-07-16 2022-12-21 Multivalent and multispecific DR5-binding fusion proteins

Publications (2)

Publication Number Publication Date
AU2016291701A1 AU2016291701A1 (en) 2018-01-25
AU2016291701B2 true AU2016291701B2 (en) 2022-09-29

Family

ID=57757772

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016291701A Active AU2016291701B2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific DR5-binding fusion proteins
AU2022291498A Pending AU2022291498A1 (en) 2015-07-16 2022-12-21 Multivalent and multispecific DR5-binding fusion proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022291498A Pending AU2022291498A1 (en) 2015-07-16 2022-12-21 Multivalent and multispecific DR5-binding fusion proteins

Country Status (25)

Country Link
US (4) US10308720B2 (enExample)
EP (2) EP3798232A1 (enExample)
JP (4) JP6807606B2 (enExample)
KR (2) KR102760380B1 (enExample)
CN (2) CN114106178A (enExample)
AU (2) AU2016291701B2 (enExample)
CA (1) CA2991634A1 (enExample)
CY (1) CY1123615T1 (enExample)
DK (1) DK3322734T3 (enExample)
ES (1) ES2833773T3 (enExample)
HR (1) HRP20201785T1 (enExample)
HU (1) HUE051896T2 (enExample)
IL (3) IL307994A (enExample)
LT (1) LT3322734T (enExample)
MX (2) MX2018000523A (enExample)
NZ (1) NZ777930A (enExample)
PL (1) PL3322734T3 (enExample)
PT (1) PT3322734T (enExample)
RS (1) RS61062B1 (enExample)
RU (2) RU2021111382A (enExample)
SG (1) SG10201912410TA (enExample)
SI (1) SI3322734T1 (enExample)
SM (1) SMT202100066T1 (enExample)
WO (1) WO2017011837A2 (enExample)
ZA (1) ZA201800238B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
CN118852460A (zh) * 2017-12-28 2024-10-29 尤利乌斯·马克西米利安维尔茨堡大学 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
KR20210006913A (ko) 2018-04-11 2021-01-19 인히브릭스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
WO2021064153A1 (en) * 2019-10-01 2021-04-08 Epsilogen Ltd Hybrid antibody
EP4154910A4 (en) * 2020-06-30 2024-09-11 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
CA3208641A1 (en) * 2021-02-19 2022-08-25 Ashraf AMANULLAH Formulations of dr5 binding polypeptides
CN119365489A (zh) * 2022-04-08 2025-01-24 印希比生物科学有限公司 Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法
TW202410919A (zh) * 2022-05-23 2024-03-16 美商英伊布里克斯公司 Dr5促效劑與iap拮抗劑之組合療法
CN117285644A (zh) * 2022-06-16 2023-12-26 清华大学 一种相变调节元件及其用途
EP4594344A2 (en) 2022-09-28 2025-08-06 Valink Therapeutics Ltd Multivalent proteins and screening methods
AU2024308381A1 (en) * 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9166691A (en) * 1990-12-20 1992-07-22 Ixsys, Inc. Optimization of binding proteins
US20020147140A1 (en) 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
RU2007135030A (ru) 2005-02-24 2009-03-27 Симайнз, Инк. (Us) Композиции и способы классификации биологических образцов
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
JP2009518024A (ja) 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
LT2285408T (lt) * 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
WO2010030182A2 (en) * 2008-09-10 2010-03-18 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
US9096659B2 (en) 2009-03-18 2015-08-04 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa
US20100281003A1 (en) 2009-04-02 2010-11-04 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8623369B2 (en) 2010-04-27 2014-01-07 National Research Council Of Canada Anti-ICAM-1 single domain antibody and uses thereof
BR112013006769B1 (pt) * 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CA2822684A1 (en) 2010-12-23 2012-06-28 Intercell Austria Ag Oprf/i agents and their use in hospitalized and other patients
EA027160B1 (ru) * 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
AU2012336069A1 (en) 2011-11-07 2014-05-22 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
EP2820043B1 (en) 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
WO2014043509A2 (en) 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
BR112015010240A2 (pt) 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP3004170A1 (en) 2013-05-28 2016-04-13 VIB vzw Single domain antibodies against sod1 and their use in medicine
WO2015104994A1 (ja) * 2014-01-10 2015-07-16 学校法人帝京平成大学 組換え偏性嫌気性グラム陽性菌

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEATHER A HUET ET AL, "Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction", MABS, US, (2014-10-30), vol. 6, no. 6, pages 1560 - 1570 *
PAPADOPOULOS KYRIAKOS P ET AL, "Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody targeting the DR5 receptor", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 75, no. 5, pages 887 - 895 *

Also Published As

Publication number Publication date
EP3798232A1 (en) 2021-03-31
NZ777930A (en) 2025-05-02
JP2018522888A (ja) 2018-08-16
EP3322734B1 (en) 2020-09-09
LT3322734T (lt) 2021-02-10
RU2018102803A3 (enExample) 2019-12-27
US20190309083A1 (en) 2019-10-10
KR20180030518A (ko) 2018-03-23
KR102760380B1 (ko) 2025-01-31
US20170015753A1 (en) 2017-01-19
CN107922491B (zh) 2021-09-28
WO2017011837A2 (en) 2017-01-19
RU2018102803A (ru) 2019-08-19
CA2991634A1 (en) 2017-01-19
MX2023002379A (es) 2023-03-21
RU2021111382A (ru) 2021-05-21
IL256772A (en) 2018-03-29
RU2748620C2 (ru) 2021-05-28
KR20250017305A (ko) 2025-02-04
ES2833773T3 (es) 2021-06-15
IL256772B (en) 2022-05-01
JP7244938B2 (ja) 2023-03-23
US11976126B2 (en) 2024-05-07
ZA201800238B (en) 2021-07-28
HK1254433A1 (en) 2019-07-19
JP2021046414A (ja) 2021-03-25
IL292037A (en) 2022-06-01
WO2017011837A3 (en) 2017-03-02
AU2022291498A1 (en) 2023-02-02
JP6807606B2 (ja) 2021-01-06
HUE051896T2 (hu) 2021-03-29
IL307994A (en) 2023-12-01
MX2018000523A (es) 2018-04-13
RS61062B1 (sr) 2020-12-31
BR112018000584A2 (pt) 2018-09-11
US20240376220A1 (en) 2024-11-14
SI3322734T1 (sl) 2021-02-26
HRP20201785T1 (hr) 2021-01-22
SMT202100066T1 (it) 2021-03-15
PL3322734T3 (pl) 2021-05-04
JP2025084923A (ja) 2025-06-03
SG10201912410TA (en) 2020-02-27
CY1123615T1 (el) 2022-03-24
PT3322734T (pt) 2020-11-30
EP3322734A4 (en) 2019-04-17
EP3322734A2 (en) 2018-05-23
AU2016291701A1 (en) 2018-01-25
US20220064318A1 (en) 2022-03-03
CN114106178A (zh) 2022-03-01
US11117973B2 (en) 2021-09-14
JP2023022214A (ja) 2023-02-14
US10308720B2 (en) 2019-06-04
CN107922491A (zh) 2018-04-17
NZ738850A (en) 2024-11-29
DK3322734T3 (da) 2020-10-26

Similar Documents

Publication Publication Date Title
US11976126B2 (en) Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells
KR102570405B1 (ko) Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
KR102417687B1 (ko) Tl1a 항체 및 그의 용도
KR20210076918A (ko) 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도
RU2759949C2 (ru) Молекулы, нацеленные на систему секреции типа iii
CA3186256A1 (en) Anti-lilrb1 antibody and uses thereof
CA3217029A1 (en) Engineered dual binding antibodies and uses thereof
HK40048814A (en) Multivalent and multispecific dr5-binding fusion proteins
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
BR122025011160A2 (pt) Proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas
HK1254433B (en) Multivalent and multispecific dr5-binding fusion proteins
BR112018000584B1 (pt) Polipeptídeo isolado que se liga pelo menos ao receptor de morte 5 (dr5) e seus usos
HK40061359B (zh) 靶向c5ar的抗体

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: INHIBRX, INC.

Free format text: FORMER NAME(S): INHIBRX LP

FGA Letters patent sealed or granted (standard patent)